The efficacy of anti‐IL‐1 targeted therapy in PAPA and PASH syndrome
Abstract Introduction Pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) and pyoderma gangrenosum, acne and hidradenitis suppurativa (PASH) are rare autoinflammatory diseases. Treatment of PAPA and PASH is difficult. Conventional immunosuppressants and tumor necrosis factor (TNF) antagonists f...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-09-01
|
| Series: | JEADV Clinical Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jvc2.52 |
| _version_ | 1811210102684778496 |
|---|---|
| author | Chloé Challamel Céline Girard Laurent Misery Assia Touhouche Marion Fradet Maëlla Severino‐Freire Cristina B. Livideanu Maria P. Konstantinou Fatma Jendoubi Carle Paul |
| author_facet | Chloé Challamel Céline Girard Laurent Misery Assia Touhouche Marion Fradet Maëlla Severino‐Freire Cristina B. Livideanu Maria P. Konstantinou Fatma Jendoubi Carle Paul |
| author_sort | Chloé Challamel |
| collection | DOAJ |
| description | Abstract Introduction Pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) and pyoderma gangrenosum, acne and hidradenitis suppurativa (PASH) are rare autoinflammatory diseases. Treatment of PAPA and PASH is difficult. Conventional immunosuppressants and tumor necrosis factor (TNF) antagonists fail to control skin lesions in many patients. Materials and Methods We conducted a retrospective observational study of patients treated with interleukin‐1 (IL‐1) antagonists for PAPA or PASH syndrome. We included all PASH and PAPA treated with the IL‐1 antagonists canakinumab and anakinra in Toulouse, Brest and Montpellier, France and report on the patients' response to treatment. Results Four patients were treated with anakinra (one patient) and/or canakinumab (three patients) for 6 months to 10 years. Treatment was associated with sustained improvement of skin lesions: hidradenitis suppurativa in four patients including full resolution of skin lesions in three patients, acne with full resolution in one patient, pyoderma gangrenosum in three patients who experienced full resolution of skin lesions. Anti‐IL‐1 treatment was also associated with full resolution of symptoms associated with spondyloarthritis in one patient. One patient who had been receiving oral corticosteroids for years was able to stop treatment while on IL‐1 antagonist. Discussion IL‐1 antagonists, especially canakinumab, are useful alternatives to treat patients with PAPA or PASH syndrome, especially patients who are non‐responders to conventional treatment and TNF antagonists. |
| first_indexed | 2024-04-12T04:49:15Z |
| format | Article |
| id | doaj.art-c812b47fa58a4883b63b801df1dd2e43 |
| institution | Directory Open Access Journal |
| issn | 2768-6566 |
| language | English |
| last_indexed | 2024-04-12T04:49:15Z |
| publishDate | 2022-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | JEADV Clinical Practice |
| spelling | doaj.art-c812b47fa58a4883b63b801df1dd2e432022-12-22T03:47:21ZengWileyJEADV Clinical Practice2768-65662022-09-011327528010.1002/jvc2.52The efficacy of anti‐IL‐1 targeted therapy in PAPA and PASH syndromeChloé Challamel0Céline Girard1Laurent Misery2Assia Touhouche3Marion Fradet4Maëlla Severino‐Freire5Cristina B. Livideanu6Maria P. Konstantinou7Fatma Jendoubi8Carle Paul9Department of Dermatology CHU and Université de Toulouse Toulouse FranceDepartment of Dermatology CHU de Montpellier Montpellier FranceDepartment of Dermatology CHU de Brest Brest FranceDepartment of Dermatology CHU and Université de Toulouse Toulouse FranceDepartment of Dermatology CHU and Université de Toulouse Toulouse FranceDepartment of Dermatology CHU and Université de Toulouse Toulouse FranceDepartment of Dermatology CHU and Université de Toulouse Toulouse FranceDepartment of Dermatology CHU and Université de Toulouse Toulouse FranceDepartment of Dermatology CHU and Université de Toulouse Toulouse FranceDepartment of Dermatology CHU and Université de Toulouse Toulouse FranceAbstract Introduction Pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) and pyoderma gangrenosum, acne and hidradenitis suppurativa (PASH) are rare autoinflammatory diseases. Treatment of PAPA and PASH is difficult. Conventional immunosuppressants and tumor necrosis factor (TNF) antagonists fail to control skin lesions in many patients. Materials and Methods We conducted a retrospective observational study of patients treated with interleukin‐1 (IL‐1) antagonists for PAPA or PASH syndrome. We included all PASH and PAPA treated with the IL‐1 antagonists canakinumab and anakinra in Toulouse, Brest and Montpellier, France and report on the patients' response to treatment. Results Four patients were treated with anakinra (one patient) and/or canakinumab (three patients) for 6 months to 10 years. Treatment was associated with sustained improvement of skin lesions: hidradenitis suppurativa in four patients including full resolution of skin lesions in three patients, acne with full resolution in one patient, pyoderma gangrenosum in three patients who experienced full resolution of skin lesions. Anti‐IL‐1 treatment was also associated with full resolution of symptoms associated with spondyloarthritis in one patient. One patient who had been receiving oral corticosteroids for years was able to stop treatment while on IL‐1 antagonist. Discussion IL‐1 antagonists, especially canakinumab, are useful alternatives to treat patients with PAPA or PASH syndrome, especially patients who are non‐responders to conventional treatment and TNF antagonists.https://doi.org/10.1002/jvc2.52anakinraCanakinumabPAPA syndromePyoderma gangrenosum |
| spellingShingle | Chloé Challamel Céline Girard Laurent Misery Assia Touhouche Marion Fradet Maëlla Severino‐Freire Cristina B. Livideanu Maria P. Konstantinou Fatma Jendoubi Carle Paul The efficacy of anti‐IL‐1 targeted therapy in PAPA and PASH syndrome JEADV Clinical Practice anakinra Canakinumab PAPA syndrome Pyoderma gangrenosum |
| title | The efficacy of anti‐IL‐1 targeted therapy in PAPA and PASH syndrome |
| title_full | The efficacy of anti‐IL‐1 targeted therapy in PAPA and PASH syndrome |
| title_fullStr | The efficacy of anti‐IL‐1 targeted therapy in PAPA and PASH syndrome |
| title_full_unstemmed | The efficacy of anti‐IL‐1 targeted therapy in PAPA and PASH syndrome |
| title_short | The efficacy of anti‐IL‐1 targeted therapy in PAPA and PASH syndrome |
| title_sort | efficacy of anti il 1 targeted therapy in papa and pash syndrome |
| topic | anakinra Canakinumab PAPA syndrome Pyoderma gangrenosum |
| url | https://doi.org/10.1002/jvc2.52 |
| work_keys_str_mv | AT chloechallamel theefficacyofantiil1targetedtherapyinpapaandpashsyndrome AT celinegirard theefficacyofantiil1targetedtherapyinpapaandpashsyndrome AT laurentmisery theefficacyofantiil1targetedtherapyinpapaandpashsyndrome AT assiatouhouche theefficacyofantiil1targetedtherapyinpapaandpashsyndrome AT marionfradet theefficacyofantiil1targetedtherapyinpapaandpashsyndrome AT maellaseverinofreire theefficacyofantiil1targetedtherapyinpapaandpashsyndrome AT cristinablivideanu theefficacyofantiil1targetedtherapyinpapaandpashsyndrome AT mariapkonstantinou theefficacyofantiil1targetedtherapyinpapaandpashsyndrome AT fatmajendoubi theefficacyofantiil1targetedtherapyinpapaandpashsyndrome AT carlepaul theefficacyofantiil1targetedtherapyinpapaandpashsyndrome AT chloechallamel efficacyofantiil1targetedtherapyinpapaandpashsyndrome AT celinegirard efficacyofantiil1targetedtherapyinpapaandpashsyndrome AT laurentmisery efficacyofantiil1targetedtherapyinpapaandpashsyndrome AT assiatouhouche efficacyofantiil1targetedtherapyinpapaandpashsyndrome AT marionfradet efficacyofantiil1targetedtherapyinpapaandpashsyndrome AT maellaseverinofreire efficacyofantiil1targetedtherapyinpapaandpashsyndrome AT cristinablivideanu efficacyofantiil1targetedtherapyinpapaandpashsyndrome AT mariapkonstantinou efficacyofantiil1targetedtherapyinpapaandpashsyndrome AT fatmajendoubi efficacyofantiil1targetedtherapyinpapaandpashsyndrome AT carlepaul efficacyofantiil1targetedtherapyinpapaandpashsyndrome |